-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On March 25, AstraZeneca announced that the main analysis of the Phase 3 clinical trial of the new crown vaccine AZD1222 has obtained high-level positive results.
AZD1222 is jointly developed by Oxford University and its derivative company Vaccitech.
Compared with the previous interim analysis, the latest trial results added 49 additional cases and included a total of 190 COVID-19 patients.
These results have been submitted to the independent Data Security Monitoring Board (DSMB).
Reference materials:
Reference materials:[1] AZD1222 US Phase III primary analysis confirms safety and efficacy.
[1] AZD1222 US Phase III primary analysis confirms safety and efficacy.
▽ attention [drug Mingkang Germany ] micro-channel public number
[Medical attention Mingkang Germany ] ] micro-channel public number